DEMYSTIFYING THE VALUE OF AI FOR RARE DISEASE SCIENCE AND TREATMENT

Artificial intelligence is being heralded as the next revolution. For rare disease, that revolution is already beginning: artificial intelligence is accelerating patient diagnosis, target discovery, drug discovery, and clinical care through efforts by academic researchers, industry, and patient advocacy groups.

RSVP TO ATTEND THIS FREE SESSION 

co-produced by: 

Presented by:

OUR SPEAKERS

JOHN REYNDERS

CARRIE BURKE

VP, Data Sciences, Genomics, and Bioinformatics
Alexion Pharmaceuticals

VP, Business Development and Partnerships,
Clinithink

RANJEET ALEXIS

Investment Director
Intel Capital

DAVE BJORK

CHARLOTTE HOBBS

Director of Community Relations,
FRAXA Research Foundation

VP Research & Clinical Management,
Rady Children’s Institute for Genomic Medicine

TIM GULLIAMS

CEO & Co-Founder,
Healx

Tuesday, January 14, 4:30-5:15 pm
Hilton San Francisco Union Square

MODERATOR

All Rights Reserved. Forward ® 2020

EBD Group Inc., 3150 Pio Pico Drive, Suite 201, Carlsbad, CA, 92008